Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115667) titled 'An Exploratory Clinical Study of Lenvatinib Combined with Iparomlimab and Tuvonralimab and TACE for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma' on Dec. 30, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Anhui Medical University
Condition:
HCC
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2025-12-30
Target Sample Size: experimental group:44;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301722
Published by HT Digital Content Service...